Cargando…

Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Aagaard, Theis, Reekie, Joanne, Jørgensen, Mette, Roen, Ashley, Daugaard, Gedske, Specht, Lena, Sengeløv, Henrik, Mocroft, Amanda, Lundgren, Jens, Helleberg, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196064/
https://www.ncbi.nlm.nih.gov/pubmed/32144897
http://dx.doi.org/10.1002/cam4.2955
_version_ 1783528649159344128
author Aagaard, Theis
Reekie, Joanne
Jørgensen, Mette
Roen, Ashley
Daugaard, Gedske
Specht, Lena
Sengeløv, Henrik
Mocroft, Amanda
Lundgren, Jens
Helleberg, Marie
author_facet Aagaard, Theis
Reekie, Joanne
Jørgensen, Mette
Roen, Ashley
Daugaard, Gedske
Specht, Lena
Sengeløv, Henrik
Mocroft, Amanda
Lundgren, Jens
Helleberg, Marie
author_sort Aagaard, Theis
collection PubMed
description Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk.
format Online
Article
Text
id pubmed-7196064
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71960642020-05-04 Mortality and admission to intensive care units after febrile neutropenia in patients with cancer Aagaard, Theis Reekie, Joanne Jørgensen, Mette Roen, Ashley Daugaard, Gedske Specht, Lena Sengeløv, Henrik Mocroft, Amanda Lundgren, Jens Helleberg, Marie Cancer Med Clinical Cancer Research Febrile neutropenia (FN) is a critical complication of chemotherapy associated with increased in‐hospital mortality. However, associations with increased mortality and intensive care unit (ICU) admissions during longer follow‐up are not established. Patients treated with standard first‐line chemotherapy for solid cancers at Rigshospitalet, Denmark in 2010‐2016 were included. Incidence rate ratios (IRR) of all‐cause, infectious and cardiovascular mortality, and ICU admissions after FN were analyzed by Poisson regression. Risk factors at the time of FN were analyzed in the subpopulation of patients with FN; all‐cause mortality was further stratified by the time periods 0‐30, 31‐365, and 366+ days after FN. We included 9018 patients with gastric (14.4%) and breast (13.1%) cancer being the most common, 51.2% had locally advanced or disseminated disease and the patients had a median Charlson Comorbidity Index score of 0 (interquartile range, 0‐0). During follow‐up, 845 (9.4%) experienced FN and 4483 (49.7%) died during 18 775 person‐years of follow‐up. After adjustment, FN was associated with increased risk of all‐cause mortality, infectious mortality, and ICU admissions with IRRs of 1.39 (95% CI, 1.24‐1.56), 1.94 (95% CI, 1.43‐2.62), and 2.28 (95% CI, 1.60‐3.24). Among those with FN, having a positive blood culture and low lymphocytes were associated with excess risk of death and ICU admissions (predominantly the first 30 days after FN), while elevated C‐reactive protein and low hemoglobin predicted mortality the first year after FN. The risk of death varied according to the time since FN; adjusted IRR per additional risk factor present for the time periods 0‐30, 31‐365, and 366+ days after FN were 2.00 (95% CI, 1.45‐2.75), 1.36 (95% CI, 1.17‐1.57), and 1.17 (95% CI, 0.98‐1.41). FN was associated with increased mortality and risk of ICU admissions. An objectively identifiable subgroup of patients among those with FN carried this excess risk. John Wiley and Sons Inc. 2020-03-07 /pmc/articles/PMC7196064/ /pubmed/32144897 http://dx.doi.org/10.1002/cam4.2955 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Aagaard, Theis
Reekie, Joanne
Jørgensen, Mette
Roen, Ashley
Daugaard, Gedske
Specht, Lena
Sengeløv, Henrik
Mocroft, Amanda
Lundgren, Jens
Helleberg, Marie
Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title_full Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title_fullStr Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title_full_unstemmed Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title_short Mortality and admission to intensive care units after febrile neutropenia in patients with cancer
title_sort mortality and admission to intensive care units after febrile neutropenia in patients with cancer
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196064/
https://www.ncbi.nlm.nih.gov/pubmed/32144897
http://dx.doi.org/10.1002/cam4.2955
work_keys_str_mv AT aagaardtheis mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT reekiejoanne mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT jørgensenmette mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT roenashley mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT daugaardgedske mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT spechtlena mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT sengeløvhenrik mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT mocroftamanda mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT lundgrenjens mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer
AT hellebergmarie mortalityandadmissiontointensivecareunitsafterfebrileneutropeniainpatientswithcancer